Late Breaking Abstract - Efficacy and safety of benralizumab in patients with severe uncontrolled asthma despite ICS-LABA: a randomised, double-blind, placebo-controlled phase 3 trial in Asia (MIRACLE)

被引：0

作者：

Lai, Kefang ^{[1
]}

Sun, Dejun ^{[2
]}

Dai, Ranran ^{[3
]}

Samoro, Ronnie ^{[4
]}

Park, Hae-Sim ^{[5
]}

Astrand, Annika ^{[6
]}

Cohen, David ^{[7
]}

Jison, Maria ^{[7
]}

Shih, Vivian ^{[8
]}

Werkstrom, Viktoria ^{[6
]}

Yao, Yuhui ^{[9
]}

Zhang, Yajuan ^{[9
]}

Zheng, Wenying ^{[10
]}

Zhong, Nanshan ^{[1
]}

机构：

[1] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou, Peoples R China

[2] Inner Mongolia Peoples Hosp, Hohhot, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[4] Healthlink Med Surg Dent Clin & Diagnost Ctr, Iloilo, Philippines

[5] Ajou Univ Hosp, Suwon, South Korea

[6] AstraZeneca, Late Stage Resp & Immunol, Gothenburg, Sweden

[7] AstraZeneca, Late Stage Resp & Immunol, Gaithersburg, MD USA

[8] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[9] AstraZeneca, Resp & Immunol, R&D China, Shanghai, Peoples R China

[10] AstraZeneca, R&D China, Biometr, Shanghai, Peoples R China

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.PA4130

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[1] Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
Brightling, Christopher E.
Chanez, Pascal
Leigh, Richard
O'Byrne, Paul M.
Korn, Stephanie
She, Dewei
May, Richard D.
Streicher, Katie
Ranade, Koustubh
Piper, Edward
LANCET RESPIRATORY MEDICINE, 2015, 3 (09): : 692 - 701
[2] Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial
Gauvreau, Gail M.
Sehmi, Roma
Fitzgerald, J. Mark
Leigh, Richard
Cockcroft, Donald W.
Davis, Beth E.
Mayers, Irvin
Boulet, Louis-Philippe
Al-Sajee, Dhuha
Salter, Brittany M.
Cusack, Ruth P.
Ho, Terence
Whetstone, Christiane E.
Alsaji, Nadia
Satia, Imran
Killian, Kieran J.
Mitchell, Patrick D.
Magee, Iain P.
Bergeron, Celine
Bhutani, Mohit
Werkstrom, Viktoria
Durzynski, Tomasz
Shoemaker, Kathryn
Katial, Rohit K.
Jison, Maria
Newbold, Paul
Mccrae, Christopher
O'byrne, Paul M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (03)
[3] Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Ferguson, Gary T.
FitzGerald, J. Mark
Bleecker, Eugene R.
Laviolette, Michel
Bernstein, David
LaForce, Craig
Mansfield, Lyndon
Barker, Peter
Wu, Yanping
Jison, Maria
Goldman, Mitchell
LANCET RESPIRATORY MEDICINE, 2017, 5 (07): : 568 - 576
[4] Efficacy, Safety, and Tolerability of Lebrikizumab in Adolescent Patients with Uncontrolled Asthma (ACOUSTICS): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study
Szefler, S.
Roberts, G.
Rubin, A. S.
Zielen, S.
Kuna, P.
Alpan, O.
Anzures-Cabrera, J.
Chen, Q.
Holweg, C. T. J.
Kaminski, J.
Putnam, W.
Matthews, J. G.
Kamath, N.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[5] Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Chen, Ruchong
Wei, Liping
Dai, Yuanrong
Wang, Zaiyi
Yang, Danrong
Jin, Meiling
Xiong, Cui
Li, Ting
Hu, Shuling
Song, Jie
Chan, Robert
Kumar, Subramanya
Abdelkarim, Azza
Zhong, Nanshan
ERJ OPEN RESEARCH, 2024, 10 (03)
[6] Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Hanania, Nicola A.
Korenblat, Phillip
Chapman, Kenneth R.
Bateman, Eric D.
Kopecky, Petr
Paggiaro, Pierluigi
Yokoyama, Akihito
Olsson, Julie
Gray, Sarah
Holweg, Cecile T. J.
Eisner, Mark
Asare, Charles
Fischer, Saloumeh K.
Peng, Kun
Putnam, Wendy S.
Matthews, John G.
LANCET RESPIRATORY MEDICINE, 2016, 4 (10): : 781 - 796
[7] LATE-BREAKING ABSTRACT: The benefits of Nigella sativa oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial
Koshak, Abdulrahman
Wei, Li
Koshak, Emad
Wali, Siraj
Alamoudi, Omer
Demerdash, Abdulrahman
Qutub, Majdy
Pushparaj, Peter
Heinrich, Michael
EUROPEAN RESPIRATORY JOURNAL, 2016, 48
[8] Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind randomised, placebo-controlled trial
Ovchinsky, Nadia
Aumar, Madeleine
Baker, Alastair
Baumann, Ulrich
Butler, Philip
Cananzi, Mara
Czubkowski, Piotr
Durmaz, Oezlem
Fischer, Ryan
Indolfi, Giuseppe
Karnsakul, Wikrom W.
Lacaille, Florence
Lee, Way S.
Maggiore, Giuseppe
Rosenthal, Philip
Ruiz, Mathias
Sokal, Etienne
Sturm, Ekkehard
Woerd, Wendy van der
Verkade, Henkjan J.
Wehrman, Andrew
Clemson, Christine
Yu, Qifeng
Ni, Quanhong
Ruvido, Jessica
Manganaro, Susan
Mattsson, Jan P.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (07): : 632 - 645
[9] Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
FitzGerald, J. Mark
Bleecker, Eugene R.
Nair, Parameswaran
Korn, Stephanie
Ohta, Ken
Lommatzsch, Marek
Ferguson, Gary T.
Busse, William W.
Barker, Peter
Sproule, Stephanie
Gilmartin, Geoffrey
Werkstrom, Viktoria
Aurivillius, Magnus
Goldman, Mitchell
LANCET, 2016, 388 (10056): : 2128 - 2141
[10] EFFICACY AND SAFETY OF PRUCALOPRIDE IN MEN WITH CHRONIC CONSTIPATION: A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Yiannakou, Y.
Bouchoucha, M.
Schiefke, I.
Piessevaux, H.
Filip, R.
Gabalec, L.
Stephenson, D.
Kerstens, R.
Etherson, K.
Levine, A.
GUT, 2015, 64 : A323 - A324

← 1 2 3 4 5 →